@inbook{e659d4da62504c9eb4795863149b2346,
title = "New antibiotic development for pulmonary infections: New drugs for bad bugs and beyond",
abstract = "Antimicrobial resistance has been recognised as a public health threat on a global scale, causing at least 700 000 death cases every year, which is predicted to increase to 10 million deaths per year in 2050 if no measures to contain antimicrobial resistance are taken. This rapidly spreading menace has made many antibiotics obsolete, which, together with the slow pace of clinical development of new antibacterials, has nearly desiccated the antibiotic pipeline, leaving fewer treatment options for many infections, including LRTIs. The few recently approved antibiotics and molecules in the final stages of clinical development could potentially be the light at the end of the tunnel for the treatment of LRTIs. Concerted action is needed to effectively confront antimicrobial resistance and deliver novel strategies for the treatment of infections caused by MDR bacteria. A multidisciplinary network, such as that created under the New Drugs for Bad Bugs programme, would play a crucial role in improving the efficiency of anti-infective trials.",
author = "MJM Bonten and Herman Goossens and Tomislav Kostyanev",
note = "Publisher Copyright: {\textcopyright} ERS 2017.",
year = "2017",
month = mar,
day = "1",
doi = "10.1183/2312508X.10006116",
language = "English",
series = "ERS Monograph",
publisher = "European Respiratory Society",
pages = "289--301",
editor = "Stefano Aliberti and Chalmers, \{James D.\} and Pletz, \{Mathias W.\}",
booktitle = "Anti-infectives and the Lung",
address = "Switzerland",
}